Amgen
As on 01 Jan, 2026 | 02:29 IST
| Open | 328.98 |
| Previous Close | 328.69 |
| Beta | 0.04 |
| High | 329.18 |
| Low | 327.10 |
| TTM EPS See historical trend | 21.87(+13.79% YoY) |
| 52 Week High | 346.38 |
| 52 Week Low | 257.13 |
| TTM PE See historical trend | 14.97(Low PE) |
| Mkt. Cap ($ Billion) | 175.96 |
| Dividend Yield | 3.33 |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 330.01 |
| 10 | 328.57 |
| 20 | 327.52 |
| 50 | 322.52 |
| 100 | 304.86 |
| 200 | 299.61 |
Returns
| 1 Week | -1.25% | |
| 1 Month | -5.24% | |
| 3 Months | 16.00% | |
| YTD | 25.62% | |
| 1 Year | 25.62% | |
| 3 Years | 24.68% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | 1,074.68 | -0.47 | 1,022.18 | 48.89 | 21.99 | 0.74 | 1,111.99/623.99 | 0.06 | Very Bullish |
| J&J | 206.95 | 0.02 | 498.78 | 19.94 | 10.38 | 2.83 | 215.04/141.30 | 0.14 | Very Bullish |
| AbbVie | 228.49 | -0.54 | 403.74 | 24.18 | 9.45 | 3.49 | 244.80/164.59 | 0.34 | Very Bullish |
| Merck | 105.26 | -0.75 | 266.69 | 12.17 | 8.65 | 3.86 | 107.59/73.35 | 0.65 | Very Bullish |
| Amgen | 327.31 | -0.42 | 175.96 | 14.97 | 21.87 | 3.33 | 346.38/257.13 | -5.24 | Bullish |
Market news
- Dow, S&P 500 close at record highs as Santa rally startsDecember 25, 2025 8:04 AM
- Stocks rise with tech boost, yen weakens after Japan rate hikeDecember 20, 2025 12:20 PM
- Wall Street ends lower; fears of AI bubble and inflation send investors awayDecember 13, 2025 9:01 AM
- Wall Street closes with slight gains as data keeps Fed cut expectations on trackDecember 6, 2025 8:34 AM
About the company
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.